

# A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program

**Subotheni Thavaneswaran** (✉ [s.thavaneswaran@garvan.org.au](mailto:s.thavaneswaran@garvan.org.au))

Garvan Institute of Medical Research, University of NSW

**Lucille Sebastian**

The NHMRC Clinical Trials Centre, University of Sydney

**Maya Kansara**

Garvan Institute of Medical Research, University of NSW

**Mandy Ballinger**

Garvan Institute of Medical Research, University of NSW

**David Espinoza**

The NHMRC Clinical Trials Centre, University of Sydney

**Frank Lin**

Garvan Institute of Medical Research, University of NSW

**Chee Lee**

The NHMRC Clinical Trials Centre, University of Sydney

**Katrin Sjoquist**

The NHMRC Clinical Trials Centre, University of Sydney

**John Grady**

Garvan Institute of Medical Research, University of NSW

**Mark Cowley**

Children's Cancer Institute Australia

**Anthony Joshua**

The Kinghorn Cancer Centre, St Vincent's Hospital Sydney

**Min Qiu**

Sydney, St Vincent's Hospital Sydney

**Samantha Oakes**

Garvan Institute of Medical Research, University of NSW

**John Simes**

The NHMRC Clinical Trials Centre, University of Sydney

**David Thomas**

Garvan Institute of Medical Research, University of NSW

---

## Research Article

**Keywords:** CDK4/6 inhibitors, advanced solid cancers, molecular selection, signal-seeking phase IIa clinical trial

**DOI:** <https://doi.org/10.21203/rs.3.rs-254137/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**BACKGROUND:** The D-type cyclin and cyclin dependent kinase 4/6 (CDK) complex phosphorylates retinoblastoma protein, thereby driving cell cycle progression. This process is blocked by inhibitors of CDK4/6. As part of the Molecular Screening and Therapeutics program, this phase IIa trial tested the clinical activity of CDK4/6 inhibitor monotherapy in tumors with cell cycle pathway alterations.

**PATIENTS AND METHODS:** Eligible patients  $\geq 18$  years old, with advanced or metastatic solid cancers, along with amplification of *CDK4/6*, *CCND1/2/3*, or loss of function alterations in *CDKN2A* were recruited. The primary objective of this signal-seeking trial was to evaluate the clinical activity of palbociclib – a composite of objective responses and the ratio of time to progression (TTP) on palbociclib, to TTP on treatment preceding trial entry.

**RESULTS:** Ten patients had *CDK4/CDK6* or *Cyclin D1* amplifications, six patients had *CDKN2A* deletions. After a median follow-up of 35 months, there were no objective responses. Seven patients had stable disease and one had non-complete response/non-progressive disease (non-CR/non-PD) based on evaluation of a non-target lesion. Two of these seven patients maintained stable disease for at least 6 months, as did the patient with non-CR/non-PD. Median PFS and OS were 3.5 and 11.0 months respectively. No unexpected toxicities were observed. Translational correlates yielded strategies for targeting cell cycle interactions with other molecular pathways and the immune system.

**CONCLUSION:** Palbociclib monotherapy was not associated with any objective responses, but stable disease lasting at least 6 months was observed in 19% of patients. There was no clear relationship with alteration type or histotype. The signals of immune activation provide insights into the design of future trials, with a combination approach adding checkpoint blockade to CDK4/6 inhibition.

## Background

Cyclin D-dependent kinases 4 and 6 (CDK4 and CDK6) control cell cycle transition between G1 and the S phase, where DNA synthesis is initiated, leading to cell cycle progression (1, 2). *CDK4* acts as an oncogene in many cancers, resulting in phosphorylation and inactivation of the retinoblastoma tumour suppressor (Rb) (3–5). Aberrant activation of genes encoding cyclin D1 (*CCND1*) and CDK4 (6, 7), or inactivation of the *CDKN2A* locus, whose product p16 (INK4A) normally inhibits cyclin D-CDK4/6 kinase activity and may lead to uncontrolled cell cycle progression (8–14). Beyond its cell cycle effects, there is emerging pre-clinical evidence that CDK4/6 inhibition can reverse immune evasion by cancer cells (15–18). This includes stimulation and associated infiltration of programmed death (PD-1) expressing T-cells, improved antigen processing potential and a reduction in the CD4 + FOXP3 + Treg suppressor cells (15).

Palbociclib is a highly selective pyrido[2,3-d]pyrimidine derivative that acts as a reversible oral inhibitor of both CDK4 and CDK6 (19). Palbociclib arrests the proliferation of tumor cells that retain functional Rb, blocking its phosphorylation on CDK4/6-specific sites. It has demonstrated primarily cytostatic effects on a range of cancer cell lines (20–25), as well as in clinical trials. A phase I trial (N = 33) of palbociclib

monotherapy in Rb protein-positive advanced cancers demonstrated 3% partial response and 29% stable disease rates (26). In a phase II study (27) of advanced well-differentiated/dedifferentiated liposarcomas, characterized by *CDK4* amplification (28–30), the 12-week PFS rate was 66% (27). A phase 2 trial in Rb protein-positive advanced estrogen receptor positive breast cancer yielded 5% partial responses and 14% stable disease for at least 6 months (31). A subsequent phase 3 trial in advanced, estrogen-receptor positive breast cancer provides strong clinical evidence for the addition of palbociclib to anti-estrogen therapies as an effective method of overcoming endocrine resistance (32–34).

The Molecular Screening and Therapeutics (MoST) Program is a precision medicine platform, in which patients are assigned to treatment baskets on the basis of genomic alterations identified through genomic profiling of an archival tumor sample, irrespective of histotype, or pan-cancer (35). The MoST1 trial evaluated palbociclib monotherapy in patients whose tumors harboured cyclin-D–CDK4/6 pathway alterations. Here, we report the clinical efficacy and safety amongst patients who participated in this study.

## Materials And Methods

### Study Design and Population

The MoST Program is designed to evaluate signals of clinical activity for treatments targeting actionable genomic alterations found in any tumor type. A more detailed study overview has been published previously (35). In brief, patients with treatment-refractory, advanced cancers of any histotype underwent tumor profiling to identify eligible patients for the therapeutic studies. These studies were phase Ib/IIa open-label trials with the flexibility for individual trials to open and close whilst other baskets continued accrual.

In the MoST1 trial, we enrolled patients with solid tumors harboring *CDK4/6* or *CCND1/2/3*-amplification with six or more copies, or *CDKN2A* biallelic deletion or loss of function mutations. Patients with breast cancer, mantel cell lymphoma, myeloma and germ cell tumors were excluded. Patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2; evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (36) and adequate hepatic, renal and bone marrow function. Patients were required to have failed (or be intolerant of) standard therapies for their tumor type, and not previously received treatment with CDK inhibitors.

The study was performed in accordance with the Declaration of Helsinki, with central or institutional ethics and local research governance approval.

An independent data and safety monitoring committee provided independent assessments of patient safety and trial progress.

### Study Treatment and Assessments

Palbociclib was administered orally once daily on a 28-day cycle at 125mg for days 1 to 21 and no treatment on days 22 to 28. Treatment continued until disease progression, unmanageable toxicity, or a decision by the patient or clinician to cease. Up to three dose reductions were permitted. Treatment toxicities were evaluated using the National Cancer Institute Common Terminology Criteria, version 4.03 (37). Response assessment was performed every 8 weeks.

## Study Endpoints

The primary endpoint of the trial was to evaluate clinical activity, using a composite endpoint of objective response rate (ORR), and the ratio of time to progression (TTP) on trial (TTP2), to TTP on the last line of therapy (TTP1). In a pan-cancer setting, using patients as their own control informs the rate of change in disease trajectory for that individual, with a TTP2/TTP1 ratio of 1.3 suggesting clinical activity (38, 39). If TTP1 was not evaluable, TTP2 > 6 months was pre-specified to indicate clinical activity. Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, health-related quality of life measured by the EORTC QLQ-C30 (40), and Brief Pain Inventory (BPI) assessment (41).

Several translational correlatives were also evaluated. We examined the co-occurrence of genomic alterations – both by histotype and by molecular signatures with potential collateral effects on cell cycle pathway inhibition (42, 43). We investigated the immune effects of CDK4/6 inhibition by assessing PD-L1 status, tumor infiltrating lymphocytes (TILs) and gene expression signatures corresponding to T-cell inflammation (44) in tissue samples obtained following palbociclib treatment, compared with baseline pre-treatment/archival samples. PD-L1 expression on tumor cells was determined by immunohistochemistry (IHC) using Ventana SP263 rabbit monoclonal antibody assay. TILs were assessed using a hematoxylin and eosin-stained slide which permitted morphological discrimination of lymphocytes in the tumor and its immediate periphery, as previously described (45–49). The TILs level was calculated using the proportion TILs, of total cells on the slide. Evaluated gene expression signatures comprised of a set of 128 genes, including 5 housekeeping genes and 123 genes relating to T-cell biology, inflammation and immune response, and employing published methods (Appendix 1) (44, 50–52).

## Statistical Considerations

A response rate of 40% supports the molecular hypothesis for this trial. Using the method of Metha-Cain, boundaries for declaring similar activity was determined based on a one-sided 95% confidence interval for ORR at 6 months which would include the hypothesized rate of 40% (53). Thus, for a sample size of 16 patients, objective responses in 3 or more patients constitutes a promising signal of activity.

## Results

From November 2016 to December 2017, 16 patients were enrolled on the trial. A range of tumor types were included, with the most common histotype being bone and soft tissue sarcomas (N = 12, 75%) (Table 1). The median age was 54 years (range 19 to 75 years), and 56% were male and 56% had an ECOG PS of 0. Tumors from eight patients had *CDK4* amplification identified through tumor profiling and seven of these were orthogonally validated using fluorescent in situ hybridisation (FISH). Another six

patients had biallelic loss of *CDKN2A*, also orthogonally validated by FISH or IHC. The remaining two patients had more than one pathway alteration (Table 1).

Table 1  
Baseline characteristics including molecular eligibility and validation (n = 16)

Characteristic	No.	%		
Median age, years (range)	54	(19 to 75)		
Male sex	9	56		
ECOG status				
0	9	56		
1	6	38		
2	1	6		
Median lines of systemic therapy (range)	2	(0–5)		
<b>Cancer type</b>			<b>Molecular eligibility</b>	<b>Orthogonal validation status and method</b>
<b>Bone and soft tissue sarcomas</b>	<b>12</b>	<b>75</b>		
Alveolar rhabdomyosarcoma	1	6	<i>CDK4</i> amplification	Validated by FISH
Chordoma	2	13	Biallelic loss of <i>CDKN2A</i>	Validated by FISH
Liposarcoma	6	38	<i>CDK4</i> amplification	5 validated by FISH, 1 unvalidated
Osteosarcoma	2	13	<i>CDK4</i> ; <i>CDK6</i> and <i>CCND3</i> amplification	<i>CDK4</i> amplification validated by FISH, <i>CDK6</i> amplification by PCR
Solitary fibrous tumor	1	6	Biallelic loss of <i>CDKN2A</i>	Validated by FISH
<b>Carcinomas</b>	<b>4</b>	<b>25</b>		
Adrenal cortical carcinoma	1	6	Biallelic loss of <i>CDKN2A</i>	Validated by IHC
Pancreatic adenocarcinoma	2	13	Biallelic loss of <i>CDKN2A</i>	1 validated by FISH, 1 unvalidated
Small cell carcinoma	1	6	Biallelic loss of <i>CDKN2A</i> of <i>CCND1</i> amplification	<i>CCND1</i> amplification validated by FISH

Abbreviations: FISH - fluorescent in situ hybridization, IHC – immunohistochemistry.

Amongst enrolled patients, only 15 had RECIST measurable disease at baseline. After a median follow-up of 35 months, no patients achieved a complete or partial response. Seven patients achieved stable disease, with two patients maintaining stable disease for at least 6 months. All patients achieving stable disease had tumors with *CDK4* or *CDKN2A* alterations. One additional patient with no target lesion at baseline achieved a non-complete response/non-progressive disease by evaluation of the non-target lesion, which was also maintained for > 6 months. Eight patients had progressive disease as their best response, four confirmed radiologically and the remainder based on clinical progression.

Information on TTP from a previous line of therapy before study enrolment was available for only five patients (Appendix 2). Two of these five patients achieved a ratio of  $\geq 1.3$  for TTP on study compared with a previous line of treatment. The swimmer plot details TTP2 data, end of treatment, best response and death date by individual patient (Fig. 1).

Abbreviations: EOT – end of treatment, PD – progressive disease

The median PFS was 3.5 months (95% CI 1.8 to 5.4 months), and the 6-month PFS-rate was 16% (95% CI 3 to 38%). The median OS was 11.0 months (95% CI 4.3 to 32.0 months). The 6-month and 12-month OS rates were 63% (95% CI 35 to 81) and 44% (95% CI 20–66%) respectively (Fig. 2).

The most common adverse events (AEs) included general disorders (n = 14, 88% of patients) – comprised mainly of fatigue and pain; gastrointestinal disorders (n = 12, 75%) and cytopenias (n = 11, 69%), including anemia (n = 7, 44%), neutropenia (n = 7, 44%), and thrombocytopenia (n = 4, 25%). Grade 3 or worse adverse events were reported in 10 patients, and were comprised mainly of neutropenia, anemia, fever and sepsis (Appendix 3).

The median relative dose intensity (the ratio of administered doses to planned doses) was 97%. The dose of palbociclib was reduced in three patients (19%), with two of these patients also requiring treatment delays. An additional three patients (19%) required dose delays without dose reductions. There were no permanent treatment discontinuations due to toxicity.

The mean global EORTC QLQ-C30 was 15 points poorer on study (range – 41.7 points worse, to 4.2 points better) compared with baseline. The mean BPI score improved on study by 0.25 points (range – 5.25 points better to 1.96 points worse) compared with baseline, while the mean pain severity score was 0.29 points worse (range – 1.5 points better to 1.75 points worse) compared with baseline.

## Translational correlates

The most common co-occurring molecular alterations were in *MDM2* (n = 6 liposarcomas, n = 1 osteosarcoma), *TP53* (n = 2 pancreatic adenocarcinomas, n = 1 osteosarcoma), *KRAS* (n = 2 pancreatic adenocarcinomas, n = 1 osteosarcoma) and *NF1* (n = 1 pancreatic adenocarcinoma, n = 1 adenoid cystic carcinoma) (Fig. 3).

Three patients who had tumor samples obtained post-progression were evaluated in detail. One patient (P003) progressed after only two cycles of palbociclib with new brain metastases. A resected brain metastasis demonstrated no PD-L1 expression and very few TILs. Despite this, radiotherapy to the resection cavity followed by dual checkpoint blockade resulted in a partial RECIST response within the extensive lung metastases. Another patient (P009) received five cycles of palbociclib, with SD as best response. Tissue obtained at progression within the vertebral column displayed no PD-L1 expression and a 2-fold decline in TILs compared to the archival sample. On the other hand, one tumor sample (P001) obtained after exposure to four cycles of palbociclib and nine months of dual checkpoint blockade demonstrated a 30-fold increase in PD-L1 expression, 1.25-fold increase in immune cell PD-L1 expression and a 2-fold decline in TILs. There was also an upregulation of genes associated with immune activation and T-cell activation based on gene expression signatures (Appendix 4). This patient's best response on both treatments was SD.

## Discussion

In this study there were no objective responses observed, however three patients (19%) maintained SD or non-CR/ non-PD for at least 6 months and two additional patients (13%) achieved a TTP2 to TTP1 ratio of > 1.3. Despite the absence of any objective responses, the median PFS and OS were 3.5 months and 7.5 months respectively. Taken together, these constitute weak evidence for clinical activity. Palbociclib was well-tolerated and AEs reported in this trial were consistent with other studies (27, 31). This study also reports supplementary translational correlates that can improve our understanding of the totality of effects of CDK4/6 inhibition.

A comparison to other studies that employed molecular selection demonstrates similar outcomes as our trial, with a histologically diverse patient population. The TAPUR study which evaluated palbociclib in a range of advanced cancer types, selected on the basis of *CDKN2A* alterations reported a disease control rate of 31% and 0% at 16 weeks in the non-small cell lung cancer (NSCLC) and pancreatic/biliary cancer cohorts, respectively (54, 55). The median PFS and OS of our trial (14 weeks and 30 weeks respectively) were also consistent with the TAPUR study for the pancreas (7.2 and 12.4 weeks), biliary (7.3 weeks and 11.1 weeks) and NSCLC (8.1 and 21.6 weeks) cohorts. Additionally, the 12-week PFS rate of 56% in our trial is consistent with the phase 2 liposarcoma trial with 12-week PFS rate of 66% (27). However, given the histological diversity and small representation of each tumor type in our study, comparisons according to histotype specific PFS or OS are limited. In the advanced breast cancer setting, the addition of palbociclib to endocrine therapy has demonstrated significant improvements in PFS (32). The rationale for its addition is founded on a notable emergence of cell cycle pathway alterations associated with estrogen resistance (56). An analysis performed within a subset of patients with *PIK3CA* mutations, indicating an alternative mechanism of endocrine resistance, demonstrated a comparable improvement in PFS (HR 0.45 and 0.48) to their *PIK3CA* wildtype counterparts, despite the absence of improved objective response rates (57). Taken together, these data support a predominantly cytostatic, rather than cytotoxic effect of palbociclib and highlight the potential importance of examining co-occurring mutations.

CDK4/6 activity serves as the common pathway between several extracellular signaling pathways and the cell cycle (58, 59). Prior studies have demonstrated that co-occurring molecular alterations can potentiate tumor senescence with CDK4/6 inhibition, where subsequent growth signals do not re-instate cell cycle progression (60–65). Important molecular aberrations include *MDM2* downregulation, chromatin-remodeling enzyme *ATRX* redistribution and repression of *HRAS* transcription (62, 66). In our trial, all six liposarcomas and an osteosarcoma demonstrated *MDM2* amplification, with other common alterations consisting of *TP53*, *KRAS* and *NF1*. Of these genes, particular alteration types in *MDM2*, *KRAS* and *NF1* are potentially also therapeutically actionable (67–70) and should be investigated in future studies of combinatory treatments to promote senescence. Furthermore, mechanisms beyond canonical cyclin-D–CDK4/6 pathway inhibition, involving immune detection and tumor eradication are increasingly recognized (71, 72). Previous studies have shown that CDK4/6 can enhance effector CD8 T-cell activity. Decreased overall TILs in the tumor microenvironment in two of the cases may reflect a reduction in the proliferation of suppressor regulatory T-cells, as has been observed with CDK4/6 inhibition in preclinical models (73). In the limited number of biospecimens available post-palbociclib treatment, we demonstrated a shift in immune parameters and improved disease control with checkpoint inhibitors as subsequent trial treatment. This provides further rationale for evaluating a combinatory approach – in this case, cell cycle inhibition with palbociclib and immune checkpoint blockade, in future studies.

This study has several strengths. It recruited rapidly, collected meaningful clinical data, and discovered important hypothesis-generating molecular findings in the translational work that could inform the design of future trials. This study also has limitations. Inherent within a basket study design, the patient population consisted of a diverse range of tumor histotypes, with significant reliance on genomic biomarkers to define a common biological driver or pathway. The broad molecular eligibility may have been insufficient to optimize patient selection, and limited its signal seeking capacity. In the advanced breast cancer setting, no molecular features have emerged beyond estrogen receptor positivity (56), and the true predictive nature of *CDK4* amplification in liposarcomas is questionable, since 90% of these cancers display this particular molecular alteration (27, 74). In the absence of any objective tumor responses, quantifying benefits based on long-term outcomes using endpoints such as PFS is challenging, given the absence of appropriate historical controls to benchmark across a range of cancer histotypes. Using patients as their own control requires accurate data on TTP1 at study enrolment, which was not always available on this study. Limiting enrolment to those patients having recently progressed radiologically on their penultimate line of therapy would also facilitate interpretation of disease stabilisation.

The findings of our study have several implications. The translational correlates provide first hand insights into the logical development of future concepts. In this particular instance, the signals of immune activation provide further supportive rationale for tumor priming with CDK4/6 inhibition, followed by immune checkpoint blockade to increase the likelihood of an effective anti-tumor immune response (15, 16, 18). In fact, a MoST trial evaluating palbociclib plus avelumab, an immune checkpoint inhibitor is due to open shortly (Clinical trial registration number: ACTRN12620000568910p). Similarly, co-occurring mutations can also provide insights into worthwhile targeted therapy combinations with

potential for synergistic effects (75–77). In the presence of histological diversity, evaluating the effectiveness of a targeted therapy in the presence of a particular genomic target requires sufficient patient numbers and can be achieved more efficiently through international collaboration, particularly in rare and less common cancers.

In conclusion, palbociclib monotherapy has limited clinical activity in this study. Its proposed effects on the tumor microenvironment and immune cells is encouraging and warrants further evaluation of combination therapeutic strategies of CDK4/6 and immune checkpoint inhibition.

## **Declarations**

### **Ethics approval and consent to participate**

Ethics approval was provided by the St Vincent's Hospital Human Research Ethics Committee and all patients were at least 18 years of age and provided written informed consent to partake in the trial.

### **Consent for publication**

Not applicable.

### **Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **Competing interests**

Not applicable.

### **Funding**

We would like to acknowledge trial funding provided by the Commonwealth Government of Australia via Omico, Health Administration Corporation, NSW Ministry of Health, the Vodafone Foundation, and Pfizer Australia Pty Ltd. DMT was supported by National Health and Medical Research Council Fellowship (Regkey 1104364).

### **Authors' contributions**

LS, MB, DE, CL, KS, JS and DT were involved in the conception and design of the trial. Data collection was performed by ST, LS, MK, MB, MC and MRQ and SO. Data analysis and interpretation was performed by ST, MK, DE, FL, CL, JG, MC, AJ, JS and DT. ST, MK, DE, FL, CL and DT drafted the manuscript. All authors contributed to critical revision of the manuscript and approved the final published version.

### **Acknowledgements**

We would like to acknowledge trial funding provided by the Commonwealth Government of Australia via Omico, Health Administration Corporation, NSW Ministry of Health, the Vodafone Foundation, and Pfizer Australia Pty Ltd. DMT was supported by National Health and Medical Research Council Fellowship (Regkey 1104364). We would also like to acknowledge The Kinghorn Cancer Centre Clinical Trials team, the Garvan MoST team and The NHMRC Clinical Trials team.

## References

1. Pardee A. G1 events and regulation of cell proliferation. *Science*. 1989;246(4930):603-8.
2. VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment. *Clinical Cancer Research*. 2015;21(13):2905-10.
3. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. *Cell*. 1991;65(6):1053-61.
4. Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell*. 1995;81(3):323-30.
5. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. *Nature Reviews Cancer*. 2002;2(12):910-7.
6. Erikson J, Finan J, Tsujimoto Y, Nowell PC, Croce CM. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. *Proceedings of the National Academy of Sciences*. 1984;81(13):4144-8.
7. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. *Genes, chromosomes & cancer*. 1998;22(2):157-63.
8. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. *Molecular and Cellular Biology*. 1995;15(5):2672-81.
9. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature*. 1993;366(6456):704-7.
10. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. *Molecular medicine (Cambridge, Mass)*. 1997;3(1):5-20.
11. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. *eLife*. 2014;3:e02872.
12. Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. *Cell*. 1989;58(6):1097-105.
13. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. *Genes Dev*. 1993;7(3):331-42.
14. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell*.

- 1999;98(6):859-69.
15. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. *Cancer Discov.* 2018;8(2):216-33.
  16. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. *Nature.* 2018;553(7686):91-5.
  17. Chaikovsky AC, Sage J. Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition. *Molecular cancer research : MCR.* 2018;16(10):1454-7.
  18. Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. *Nature.* 2017;548(7668):471-5.
  19. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Molecular Cancer Therapeutics.* 2004;3(11):1427-38.
  20. Heijink DM, Fehrmann RS, de Vries EG, Koornstra JJ, Oosterhuis D, van der Zee AG, et al. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. *Oncogene.* 2011;30(17):2026-36.
  21. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. *Cell cycle (Georgetown, Tex).* 2012;11(14):2756-61.
  22. Liu F, Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. *Mol Cancer Ther.* 2012;11(10):2138-48.
  23. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. *Blood.* 2012;119(20):4597-607.
  24. Katsumi Y, Iehara T, Miyachi M, Yagyu S, Tsubai-Shimizu S, Kikuchi K, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. *Biochemical and biophysical research communications.* 2011;413(1):62-8.
  25. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research.* 2011;17(6):1591-602.
  26. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). *British journal of cancer.* 2011;104(12):1862-8.
  27. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol.* 2013;31(16):2024-8.
  28. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated

- liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. *The American journal of surgical pathology*. 2005;29(10):1340-7.
29. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. *The American journal of surgical pathology*. 2007;31(10):1476-89.
30. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. *Nature genetics*. 2010;42(8):715-21.
31. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb<sup>+</sup> Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. *Clinical Cancer Research*. 2015;21(5):995-1001.
32. Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. *Lancet Oncol*. 2020;21(2):250-60.
33. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. *New England Journal of Medicine*. 2016;375(20):1925-36.
34. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *N Engl J Med*. 2018;379(20):1926-36.
35. Thavaneswaran S, Sebastian L, Ballinger M, Best M, Hess D, Lee CK, et al. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. *Med J Aust*. 2018.
36. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-47.
37. NCI. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 2009 [Available from: [http://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm](http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm)].
38. Hoff DDV, Jr JJS, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. *Journal of Clinical Oncology*. 2010;28(33):4877-83.
39. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nature medicine*. 2019;25(5):744-50.
40. Aaronson N, Bergman B, Bullinger M, Ahmedzai S, Bergman B, Bullinger M, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85:365-76.

41. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Annals of the Academy of Medicine, Singapore*. 1994;23(2):129-38.
42. Shibayama T, Chin YM, Ono M, Kobayashi T, Chan HT, Hara F, et al. Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer. *Cancer Res*. 2020;80(4 Supplement):P5-01-15-P5-01-15.
43. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. *Cancer Discov*. 2016;6(4):353-67.
44. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN- $\gamma$ -related mRNA profile predicts clinical response to PD-1 blockade. *The Journal of Clinical Investigation*. 2017;127(8):2930-40.
45. Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, et al. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. *Oncoimmunology*. 2016;5(11):e1235107.
46. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. *Journal of Clinical Oncology*. 2012;30(21):2678-83.
47. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, et al. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015;21(14):3140-8.
48. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2012;18(5):1386-94.
49. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment cell & melanoma research*. 2015;28(3):245-53.
50. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. *Cancer immunology, immunotherapy : CII*. 2012;61(7):1019-31.
51. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515(7528):563-7.
52. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Albright A, et al. Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors. *Journal for Immunotherapy of Cancer*. 2015;3(Suppl 2):P80-P.
53. Mehta CR, Cain KC. Charts for the early stopping of pilot studies. *J Clin Oncol*. 1984;2(6):676-82.
54. Ahn ER, Mangat PK, Garrett-Mayer E, Halabi S, Dib EG, Haggstrom DE, et al. Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. *JCO Precision Oncology*. 2020(4):757-66.

55. Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. *JCO Precision Oncology*. 2019(3):1-8.
56. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res*. 2009;11(5):R77.
57. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17(4):425-39.
58. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes & development*. 1999;13(12):1501-12.
59. Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. *Nat Rev Mol Cell Biol*. 2016;17(5):280-92.
60. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. *Cancer Res*. 2006;66(15):7661-7.
61. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. *Cancer cell*. 2012;22(4):438-51.
62. Kovatcheva M, Liu DD, Dickson MA, Klein ME, O'Connor R, Wilder FO, et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. *Oncotarget*. 2015;6(10):8226-43.
63. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. *Cancer Res*. 2010;70(8):3228-38.
64. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. *Cancer cell*. 2010;18(1):63-73.
65. Rodier F, Campisi J. Four faces of cellular senescence. *The Journal of cell biology*. 2011;192(4):547-56.
66. Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, et al. ATRX is a regulator of therapy induced senescence in human cells. *Nature Communications*. 2017;8(1):386.
67. Bauer TM, Gounder MM, Weise AM, Schwartz GK, Carvajal RD, Kumar P, et al. A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). *Journal of Clinical Oncology*. 2018;36(15\_suppl):11514-.
68. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I

- Dose-Escalation and Expansion Study. *Cancer Discov.* 2018;8(2):184-95.
69. Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadad S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. *Cancer Cell.* 2014;25(5):697-710.
  70. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. *Lancet Oncol.* 2019;20(7):1011-22.
  71. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. *Developmental cell.* 2008;14(2):159-69.
  72. Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. *Genes & development.* 2004;18(8):851-5.
  73. Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. *New England Journal of Medicine.* 2006;355(11):1114-23.
  74. Dickson MA, Schwartz GK, Keohan ML, D'Angelo SP, Gounder MM, Chi P, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. *JAMA Oncol.* 2016;2(7):937-40.
  75. Teo ZL, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff CP, et al. Combined CDK4/6 and PI3K $\alpha$  Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. *Cancer Res.* 2017;77(22):6340-52.
  76. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. *Cancer Cell.* 2016;29(3):255-69.
  77. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. *Cancer Cell.* 2014;26(1):136-49.